NCT02871752 (REASSUREME) is a NA clinical trial of Health promotion in Prostate Cancer, sponsored by Northwestern University.

Who is sponsoring NCT02871752?

NCT02871752 is sponsored by Northwestern University.

What drugs are being tested in NCT02871752?

Interventions in NCT02871752: Health promotion.

What condition does NCT02871752 study?

NCT02871752 studies Prostate Cancer.

Is NCT02871752 still recruiting?

NCT02871752 is currently completed. Last updated 13 March 2023.

Last reviewed 2023-03-13 · How we verify

NCT02871752: REASSUREME

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education

Completed NA Last updated 13 March 2023

What this trial tests

NA trial testing Health promotion in Prostate Cancer in 225 participants. Completed in 30 January 2023.

Timeline

10 August 2016

Primary endpoint
30 January 2023

30 January 2023

Quick facts

Lead sponsor	Northwestern University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	225
Start date	10 August 2016
Primary completion	30 January 2023
Estimated completion	30 January 2023
Sites	4 locations across United States

Drugs / interventions tested

Health promotion

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Northwestern University

Who can join

18 and older, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We propose to examine the efficacy of couples-based mindfulness-based stress reduction (MBSR) on positive and negative psychological responses to active surveillance (AS) and AS adherence, with a sample of men on AS and their spouses.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.
Wallis CJD, Catto JWF, Finelli A, Glaser AW, et al · · 2020 · cited 34× · PMID 32893062 · DOI 10.1016/j.eururo.2020.08.030
A Scoping Review of Positive Lifestyle and Wellness Interventions to Inform the Development of a Comprehensive Health Promotion Program: "HealthPro".
Schuette SAP, Cordero E, Slosburg K, Addington EL, et al · · 2019 · cited 8× · PMID 31285713 · DOI 10.1177/1559827617704825
Mindfulness-based stress reduction for men on active surveillance for prostate cancer and their spouses: Design and methodology of a randomized controlled trial.
Victorson D, Morgan T, Kutikov A, Novakovic K, et al · · 2023 · cited 4× · PMID 36563902 · DOI 10.1016/j.cct.2022.107059

Verify or expand the search:

Other trials of Health promotion

Trials testing the same drug.

NCT06844786 — SCORE! ACTIVE Trial · NA · recruiting
NCT06131411 — Cardio-metabolic Diseases in Immigrants and Ethnic Minorities: From Epidemiology to New Prevention Strategies · NA · completed
NCT05898503 — Effects of Different Types of Exercise on Cognitive Function in Postmenopausal Hypertensive Women · NA · unknown

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Northwestern University trials

Trials by the same sponsor.

NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02871752 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 13 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02871752.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing